Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. USO
2. DHR
3. AMD
4. NVDA
5. SPY
6. GM
7. SMCI
8. GOOGL
9. TSLA
10. NOW

Go back to Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)
(NASDAQ: ERAS) Delayed: 19.51 +0.13 (0.67%)
Previous Close $19.38    52 Week High $ 
Open $18.94    52 Week Low $ 
Day High $19.81    P/E N/A 
Day Low $18.86    EPS $ 
Volume 3,076,576